research The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
Search
for
Sort by
Research
30-60 / 1000+ results
research Evaluación de la seguridad de minoxidil oral a dosis bajas en el tratamiento de la alopecia
Low-dose oral minoxidil is generally safe for treating hair loss, with mostly mild side effects.
research Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
research Combination tofacitinib and oral minoxidil treatment for severe alopecia areata
Tofacitinib and oral minoxidil together effectively regrow hair in severe alopecia areata patients.
research Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose
Oral minoxidil effectively treats hair loss, with women needing lower doses (0.25 to 2.5 mg daily) and men needing higher doses (1.25 to 5 mg daily).
research Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study
Dupilumab helps children with alopecia areata regrow hair safely.
research Topical and oral minoxidil for hair disorders in pediatric patients: What do we know so far?
Minoxidil, applied on the skin or taken orally, can improve hair growth in kids, but more research is needed due to possible side effects.
research Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
Baricitinib is an effective treatment for severe alopecia areata.
research Efficacy of Local and Whole‐Body Phototherapy for the Treatment of Various Types of Alopecia Areata
Phototherapy effectively treats certain alopecia areata types, especially if started early.
research Effectiveness and safety of baricitinib in patients with moderate‐to‐severe refractory alopecia areata in real world: An open‐label, single‐center study
Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
research Efficacy and safety of ritlecitinib, an oral JAK3 /TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
research From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
JAK inhibitors are effective for treating moderate-to-severe alopecia areata.
research Cytokine-Targeting Biologic Therapies for Alopecia Areata: A Comprehensive Review of Mechanism of Action, Clinical Efficacy, and Adverse Events
Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.
research Minoxidil oral en alopecias no androgénicas
Oral Minoxidil could be a safe and effective alternative treatment for various non-androgenic alopecias.
research Low-dose Oral Minoxidil in the Treatment of Alopecia: Evidence and Experience-based Consensus Statement of Indian Experts
Low-dose oral Minoxidil is an effective treatment for hair loss with minimal serious side effects.
research Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
New treatments for alopecia show promise in restoring hair growth by targeting immune and hormonal factors.
research Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases
New understanding and treatments for hair loss are improving, but more research is needed.
research The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
research Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
research Determining meaningful thresholds for evaluating treatment efficacy in patients with alopecia areata
A change in SALT scores of 42 or 43 indicates meaningful improvement in alopecia areata treatment.
research Quantifying Alopecia Areata via Texture Analysis to Automate the SALT Score Computation
Researchers created a fast, accurate computer program to measure hair loss in alopecia areata patients.
research 1368 Effects of phototherapy on refractory alopecia areata
Phototherapy helps some patients with alopecia areata regrow hair, especially those with hair at treatment start and less severe forms of the condition.
research Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
research Incorporation of Selenium-75 into Dog Hair
Selenium-75 stays in dog hair for up to 316 days.
research Queries and Minor Notes
The reply suggests checking for false positive or asymptomatic syphilis and using penicillin for treatment if necessary.
research 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies
Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.
research Serum sickness–like reaction in children: A retrospective review
Children's Serum Sickness-Like Reaction is often linked to antibiotics, especially amoxicillin, and involves symptoms like rash, fever, and joint issues.
research SALT Score Cards: Facilitating SALT Score Calculation in Alopecia Areata
A new tool simplifies alopecia areata severity scoring but needs validation.
research Sodium Metabisulfite: Effects on Ionic Currents and Excitotoxicity
Sodium metabisulfite increases sodium channel activity, leading to higher cell excitability and potential damage.
research Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.